Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp


Holloway, Cameron J., Murray, Andrew J., Mitchell, Kay, Martin, Daniel S., Johnson, Andrew W., Cochlin, Lowri E., Codreanu, Ion, Dhillon, Sundeep, Rodway, George W., Ashmore, Tom, Levett, Denny Z.H., Neubauer, Stefan, Montgomery, Hugh E, Grocott, Michael P.W. and Clarke, Kieran (2014) Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp High Altitude Medicine & Biology (doi:10.1089/ham.2013.1053). (PMID:24661196).

Download

Full text not available from this repository.

Description/Abstract

Abstract Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000-000, 2014.-Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48?h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300?mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3?kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp

Item Type: Article
Digital Object Identifier (DOI): doi:10.1089/ham.2013.1053
ISSNs: 1527-0297 (print)
Subjects: Q Science > QP Physiology
Organisations: Clinical & Experimental Sciences
ePrint ID: 364479
Date :
Date Event
24 March 2014Published
Date Deposited: 01 May 2014 10:40
Last Modified: 17 Apr 2017 13:53
Further Information:Google Scholar
URI: http://eprints.soton.ac.uk/id/eprint/364479

Actions (login required)

View Item View Item